RECORD // Company

Pacira BioSciences, Inc.

Formerly: Pacira Pharmaceuticals, Inc.; PACIRA INC; Blue Acquisition Corp

Built 2026-11-21T05:39:09Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (12)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Pacira Biosciences · Ctgov · exact name match to 'Pacira BioSciences, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • PACIRA BIOSCIENCES, INC. · East licences · same registered legal name as 'Pacira BioSciences, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001628280-26-071136

ItemValuePeriodFormFiledAccessionReport
Revenue$176,653,0003 months ended 2026-09-3010-Q2026-11-050001628280-26-0711362026-11-21 05:39 UTCReport an error
Net income (loss)$28,521,0003 months ended 2026-09-3010-Q2026-11-050001628280-26-0711362026-11-21 05:39 UTCReport an error
Interest expense$2,885,0003 months ended 2026-09-3010-Q2026-11-050001628280-26-0711362026-11-21 05:39 UTCReport an error
Cash and cash equivalents$246,957,000at 2026-09-3010-Q2026-11-050001628280-26-0711362026-11-21 05:39 UTCReport an error
Contract liabilities (total)$2,000,000at 2026-09-3010-Q2026-11-050001628280-26-0711362026-11-21 05:39 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001396814
Ticker
PCRX
EIN
510619477
CUSIP
695127100
Record ID
sx:sec:0001396814

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

40 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-17SEC EDGAR company profile2026-11-21 05:39 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-17SEC EDGAR company profile2026-11-21 05:39 UTCReport an error
State of incorporationDE2026-11-17SEC EDGAR company profile2026-11-21 05:39 UTCReport an error
Fiscal year end (MMDD)12312026-11-17SEC EDGAR company profile2026-11-21 05:39 UTCReport an error
Business address2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, CA, 940052026-11-17SEC EDGAR company profile2026-11-21 05:39 UTCReport an error
ExchangesNasdaq2026-11-17SEC EDGAR company profile2026-11-21 05:39 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$726,411,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 05:39 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$7,034,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 05:39 UTCReport an error
Total assets (at 2025-12-31)$1,264,917,0002025-12-3110-K, XBRL Assets2026-11-21 05:39 UTCReport an error
Stockholders' equity (at 2025-12-31)$693,111,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 05:39 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$158,545,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 05:39 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$151,994,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 05:39 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$15,333,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 05:39 UTCReport an error
Long-term debt (at 2025-12-31)$372,189,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 05:39 UTCReport an error
Operating lease liabilities (at 2025-12-31)$46,015,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 05:39 UTCReport an error
8-K Item 1.01 (filed 2026-11-17)Entry into a Material Definitive Agreement. Supplemental Indenture In connection with the consummation of the Merger (as defined below), the Company and Computershare Trust Company, National Association (the “Trustee”), entered into a First Supplemental Indenture (the “Supplemental Indenture”), dated as of November 17, 2026, which amends and supplements the Indenture (the “Original Indenture” and, together with the Supplemental Indenture, the “Indenture”), dated as of May 14, 2024, by and between the Company and the Trustee, governing the Company’s 2.125% Convertible Senior Notes due 2029 (the “Notes”), of which $287.5 million in aggregate principal amount is outstanding as of the date…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 1.02 (filed 2026-11-17)Termination of Material Definitive Agreement. In connection with the consummation of the Merger, on November 17, 2026, $96,392.50, which represented all amounts outstanding under the Credit Agreement, dated as of July 3, 2025, by and among the Company, the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank (as amended, restated, or otherwise modified from time to time, the “Credit Agreement”), was repaid in full, the Credit Agreement and all commitments thereunder were terminated and all liens securing obligations under the Credit Agreement will be released. The foregoing description of the Credit…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 2.01 (filed 2026-11-17)Completion of Acquisition or Disposition of Assets. As previously disclosed, pursuant to the Merger Agreement, on October 30, 2026, Purchaser commenced a tender offer to acquire all of the outstanding shares of common stock of the Company, $0.001 par value per share (the “Shares”), at an offer price of $36.50 per Share in cash, net of applicable withholding taxes and without interest (the “Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 30, 2026 (as amended or supplemented from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (which, together with the Offer to Purchase and other related materials…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 2.04 (filed 2026-11-17)Triggering Events that Accelerate or Increase a Direct Financial Obligations or an Obligation under an Off-Balance Sheet Arrangement. The disclosure contained under the Introductory Note and in Items 1.01, 1.02 and 2.01 above is incorporated herein by reference.2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 3.01 (filed 2026-11-17)Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 17, 2026, the Company notified The Nasdaq Global Select Market (“Nasdaq”) of the consummation of the Merger, and requested that Nasdaq (i) halt trading of the Shares prior to market open on November 17, 2026 and (ii) file with the SEC a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to effect the delisting of the Shares from Nasdaq and to deregister the Shares under Section 12(b) of the Exchange Act. In addition, the Company intends to file with the SEC a…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 3.03 (filed 2026-11-17)Material Modification to Rights of Security Holders. The disclosure contained under the Introductory Note and in Items 1.01, 2.01 and 3.01 above and in Items 5.01 and 5.03 below is incorporated herein by reference.2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 5.01 (filed 2026-11-17)Changes in Control of Registrant. The disclosure contained under the Introductory Note and in Item 2.01 above and in Items 5.02 and 5.03 below is incorporated herein by reference. As a result of the consummation of the Offer and the Merger pursuant to Section 251(h) of the DGCL, on November 17, 2026, a change in control of the Company occurred. At the Effective Time, the Company became a wholly owned subsidiary of Viatris.2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 5.02 (filed 2026-11-17)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, each of Frank D. Lee, Marcelo Bigal, Laura Brege, Christopher Christie, Mark Froimson, Samit Hirawat, Thomas Wiggans, Michael Yang and Alethia Young ceased serving as a member of the Board and each committee thereof, and each of Frank D. Lee, Shawn Cross, Kristen Williams, Brendan Teehan, Jonathan Slonin and Lauren Riker ceased serving as an officer of the Company. Further, in connection with the Merger and pursuant to the Merger Agreement, at the Effective…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 5.03 (filed 2026-11-17)Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the second amended and restated certificate of incorporation of the Company and the third amended and restated bylaws of the Company were each amended and restated in their entirety. Copies of the third amended and restated certificate of incorporation of the Company (the “Third A&R Certificate of Incorporation”) and fourth amended and restated bylaws of the Company (the “Fourth A&R Bylaws”) are filed as Exhibits 3.1 and 3.2 hereto, respectively. The foregoing description of the Third A&R Certificate of Incorporation and the…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 7.01 (filed 2026-11-17)Regulation FD Disclosure On November 17, 2026, the Company delivered notice to the holders of the Notes (the “Notice”) announcing that the closing of the Merger constitutes a Common Stock Change Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change. A copy of the Notice is filed as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act…2026-11-17SEC EDGAR 8-K 0001140361-26-044354 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 7.01 (filed 2026-11-12)Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company’s U.S. Patent No.…2026-11-12SEC EDGAR 8-K 0001140361-26-043437 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-05)As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into the Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Viatris”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary of Viatris (“Purchaser”), pursuant to which, among other things, on October 30, 2026, Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the “Shares”), of the Company for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms…2026-11-05SEC EDGAR 8-K 0001628280-26-071129 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 1.01 (filed 2026-10-08)Entry into a Material Definitive Agreement. On October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Parent”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”). Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, as promptly as practicable (but in no event more than 15 business days after the date of the Merger Agreement), Purchaser will commence a cash tender offer (the “Offer”), to acquire all of the outstanding shares of common stock of the…2026-10-08SEC EDGAR 8-K 0001104659-26-114571 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-08)On October 8, 2026, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements…2026-10-08SEC EDGAR 8-K 0001104659-26-114571 (text as filed, excerpt)2026-11-21 05:39 UTCReport an error
Plan (pension, plan no. 001)PACIRA BIOSCIENCES, INC 401(K) SALARY SAVINGS PLAN: 1,183 participants, assets $157,007,2972025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 05:39 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$170,126,3772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #2 (13F as filed): Doma Perpetual Capital Management LLC$70,472,6342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$61,046,2582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #4 (13F as filed): DIMENSIONAL FUND ADVISORS LP$53,360,1072026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #5 (13F as filed): STATE STREET CORP$52,261,6162026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #6 (13F as filed): D. E. Shaw & Co., Inc.$49,479,9232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #7 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$43,986,5312026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$42,915,1562026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #9 (13F as filed): GOLDMAN SACHS GROUP INC$38,743,2632026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$29,401,0722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 05:39 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.